Kenneth T. Mills Sells 5,000 Shares of Regenxbio Inc (RGNX) Stock

Share on StockTwits

Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 20th. The stock was sold at an average price of $66.20, for a total value of $331,000.00. Following the completion of the sale, the insider now directly owns 208,330 shares in the company, valued at $13,791,446. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Regenxbio traded up $3.65, reaching $71.20, during trading on Friday, according to Marketbeat.com. The company had a trading volume of 1,640,052 shares, compared to its average volume of 543,001. Regenxbio Inc has a 12-month low of $17.60 and a 12-month high of $71.25. The stock has a market cap of $2.13 billion, a P/E ratio of -29.06, a P/E/G ratio of 8.90 and a beta of -1.03.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, May 8th. The biotechnology company reported $3.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $2.04. Regenxbio had a return on equity of 23.27% and a net margin of 37.28%. The firm had revenue of $132.39 million for the quarter, compared to analysts’ expectations of $80.00 million. equities research analysts expect that Regenxbio Inc will post 1.89 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Regenxbio by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 248,328 shares of the biotechnology company’s stock worth $8,256,000 after acquiring an additional 2,506 shares during the last quarter. Swiss National Bank grew its stake in shares of Regenxbio by 7.7% in the first quarter. Swiss National Bank now owns 45,900 shares of the biotechnology company’s stock worth $1,370,000 after acquiring an additional 3,300 shares during the last quarter. Barclays PLC grew its stake in shares of Regenxbio by 30.9% in the first quarter. Barclays PLC now owns 20,515 shares of the biotechnology company’s stock worth $614,000 after acquiring an additional 4,837 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Regenxbio by 4.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 128,187 shares of the biotechnology company’s stock worth $4,263,000 after acquiring an additional 5,678 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Regenxbio by 12.3% in the first quarter. Victory Capital Management Inc. now owns 67,159 shares of the biotechnology company’s stock worth $2,005,000 after acquiring an additional 7,330 shares during the last quarter. 69.92% of the stock is currently owned by hedge funds and other institutional investors.

RGNX has been the topic of several recent research reports. Zacks Investment Research raised Regenxbio from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research note on Friday, March 16th. ValuEngine raised Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Chardan Capital upped their price target on Regenxbio from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, April 9th. BidaskClub raised Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. Finally, Barclays reaffirmed an “overweight” rating and issued a $48.00 price target (up from $38.00) on shares of Regenxbio in a research note on Wednesday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $43.25.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply